Trial Profile

A Phase I Study of GNX102 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GNX-102 (Primary)
Indications Acral lentiginous melanoma; Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Skin cancer; Solid tumours; Uterine cancer
Focus Adverse reactions
Sponsors GlycoNex

Most Recent Events

12 Nov 2024 According to a GlycoNex media release, GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy.
12 Nov 2024 Status changed from discontinued to completed, according to a GlycoNex media release.
23 Aug 2023 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com